FOURIER trial
A cardiovascular outcome trial for Evolocumab (a PCSK9 inhibitor) in patients with stable ASCVD, showing a 15% reduction in major adverse cardiovascular events.
Videos Mentioning FOURIER trial
Cardiovascular disease & why we should change the way we assess risk | The Peter Attia Drive Podcast
Peter Attia MD
A clinical trial for the PCSK9 inhibitor Repatha, which showed a reduction in cardiac revascularization but no change in mortality over a five-year period in heavily statinized patients with very low LDL-C.
#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain
Peter Attia MD
A landmark trial demonstrating that PCSK9 inhibitors (Repatha) significantly reduce cardiovascular events in patients with already low LDL-C on statins, even over a short period.
230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Peter Attia MD
A cardiovascular outcome trial for Evolocumab (a PCSK9 inhibitor) in patients with stable ASCVD, showing a 15% reduction in major adverse cardiovascular events.
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
A cardiovascular outcomes trial that tested PCSK9 inhibitors in patients already on statins, showing a 15% reduction in relative risk of cardiovascular events over 2.2 years.